Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis - Abdel-Rahman, O; Fouad, M (Critical reviews in oncology/hematology, 2014)